Letter of Credit (L/C) Letter of Credit at Sight (Sight L/C) Western Union Paypal Cash Against Delivery (CAD) Cash Advance (CA) Telegraphic Transfer (T/T) Cash in Advance (CID)
500 Bottle Per Week
7 Days
Yes
Sample costs shipping and taxes has to be paid by the buyer
Pack of 150 Tablets
Australia North America South America Eastern Europe Western Europe Middle East Asia Central America Africa
Manipur Nagaland Chandigarh Himachal Pradesh Pondicherry Uttarakhand Daman and Diu Dadra and Nagar Haveli Lakshadweep Gujarat South India Central India North India East India Andaman and Nicobar Islands Andhra Pradesh Assam Arunachal Pradesh Bihar Delhi Goa Jammu and Kashmir Jharkhand Karnataka Kerala Maharashtra Mizoram Meghalaya Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Haryana West Bengal Madhya Pradesh Odisha West India Chhattisgarh Uttar Pradesh All India
ISO/GMP/c-GMP/WHOGMP/USFDA/EUP
Product Description
HERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose disease has progressed after taking Trastuzumab therapy. Lapatinib is used in combination with other medication Capecitabine or Letrozole, which together, inhibit the growth of cancer cells in patients. Hetero has launched generic Lapatinib tablets, used in the treatment of advanced or metastatic breast cancer in the country. The tablets, under the brand name 'Hertab', have been launched in the strength of 250 mg, the product is marketed and distributed by Hetero Healthcare Ltd and has been made available in two stock keeping units (SKUs). The tablets are us